Trademarkia Logo

Canada

C$
KRIYA THERAPEUTICS
REGISTERED

on 29 Mar 2023

Last Applicant/ Owned by

KRIYA THERAPEUTICS INC.

4105 Hopson RdMorrisville NC 27560

US

Serial Number

2064941 filed on 15th Sept 2020

Registration Number

TMA1173298 registered on 29th Mar 2023

Registration expiry Date

15th Sept 2030

Correspondent Address

SMART & BIGGAR LP

1000 RUE DE LA GAUCHETIERE OUESTBUREAU 3300MONTREAL

QUÉBEC

CA

H3B4W5

KRIYA THERAPEUTICS

Trademark usage description

pharmaceutical preparations for use in gene therapy for the treatment of rare diseases, namely glycogen storage disease, lysosomal storage disorders, Read More

Classification Information


Class [005]
Pharmaceutical preparations for use in gene therapy for the treatment of rare diseases, namely glycogen storage disease, lysosomal storage disorders, mitochondrial disorders, fatty acid oxidation disorders; Pharmaceutical preparations for use in gene therapy for the treatment of chronic diseases, namely, diabetes, gout, arthritis, anemia, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, growth and thyroid disorders, neuromuscular diseases, namely primary periodic paralysis, glucagonoma; Pharmaceutical preparations for use in gene therapy for the treatment of ophthalmic diseases namely macular degeneration, diabetic eye disease, Retinitis pigmentosa, retinal dystrophy, dry eye disease, corneal neovascularizarization, Graves' disease, Thyroid eye disease, diabetic macular edema, diabetic retinopathy, glaucoma, uveitis, retinopathy, blue cone monochromacy, achromatopsia, Usher syndrome, Stargardt disease, cone-rod dystrophy, Leber congenital amaurosis, Leber hereditary optic neuropathy, choroideremia, Bardet-Biedl syndrome, ocular channelopathies; Pharmaceutical preparations for use in gene therapy for the treatment of oncological diseases; Pharmaceutical preparations for use in gene therapy for the treatment of lymphangiogenesic diseases; Pharmaceutical preparations for use in gene therapy for the treatment of musculoskeletal diseases, cardiovascular diseases, cardiopulmonary diseases, urological diseases, hepatological diseases, respiratory diseases, viral diseases, central and peripheral nervous system diseases, trigeminal neuralgia, chronic pain, epilepsy, Parkinson's disease, addiction, schizophrenia, depression, tauopathies, Alzheimer's disease; Pharmaceutical preparations for use in gene therapy for the treatment of diseases of the complement system, inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases, and neuroinflammatory diseases, gastrointestinal diseases, hormonal diseases, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata related diseases and disorders, auto-immune diseases, and heritable energy deficiency disorders leading to sudden death


Classification kind code

11

Class [042]
Testing, inspection, research and development of pharmaceutical preparations for gene therapy; medical and scientific research in the field of gene therapy.


Classification kind code

11

Mark Details


Serial Number

2064941

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 10th Mar 2022
Search Recorded
Submitted for opposition 20
on 10th Mar 2022
Examiner's First Report
Submitted for opposition 256
on 20th Sept 2021
Notification of Possible Opposition Sent
Submitted for opposition 48
on 15th Mar 2021
Agent Changed
Submitted for opposition 135
on 20th Jan 2021
Amendment to Application
Submitted for opposition 257
on 19th Nov 2020
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 18th Nov 2020
Created
Submitted for opposition 31
on 18th Nov 2020
Formalized
Submitted for opposition 30
on 15th Sept 2020
Filed
Submitted for opposition 228
on 15th Sept 2020
International Registration